Previous Close | 10.10 |
Open | 10.13 |
Bid | 10.11 x 300 |
Ask | 10.14 x 300 |
Day's Range | 10.02 - 10.34 |
52 Week Range | 7.72 - 27.48 |
Volume | |
Avg. Volume | 1,100,229 |
Market Cap | 1.368B |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.59 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.29 |
Subscribe to Yahoo Finance Plus to view Fair Value for VIR
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely. Regardless of the market conditions, though, the massive long-term growth runway for the biotech industry is tough to deny. The demand for better healthcare outcomes is growing, and with strengthening product pipelines, it’s best to increase your ex
Since Bill Gates left his position with Microsoft (NASDAQ:MSFT) he diversified his stock portfolio away from the tech giant. Instead, biotechnology has been is primary interest. Gates was one of the loudest voices during the Covid-19 pandemic for providing therapeutics to poor countries and elsewhere. His Bill and Melinda Gates Foundation used its clout to influence response to the disease by governments around the world. The Foundation also gave more than $1 billion to the World Health Organiza
SAN FRANCISCO, March 05, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated. This includes over 60 participants in two additional cohorts – one evaluating tobevibart given every 2 weeks and the other evaluating the